Literature DB >> 18058644

Neuronavigation and resection of lesions located in eloquent brain areas under local anesthesia and neuropsychological-neurophysiological monitoring.

M O Pinsker1, A Nabavi, H M Mehdorn.   

Abstract

BACKGROUND: The aim of this study was to determine the safety and maximal extension of tumor resection achievable with a combination of awake craniotomy under local anesthesia, neuronavigation, and continuous neuropsychological and neurophysiological monitoring in patients with lesions within the eloquent brain.
METHODS: We have performed 55 resections of different pathologies with neuronavigation on 52 patients from January 1998 to December 2002. Mean age was 49 years, the male to female ratio was 37 to 15. All patients underwent a continuous examination by a neuropsychologist and repetitive cortical stimulations during the resection, and a 3-month postoperative neurological examination to determine functional outcome. Neurological outcome and results of resection of patients with gliomas were compared to a control group of 27 patients with lesions in the central region who were operated under general anesthesia during the same time period.
RESULTS: Tumor resection was stopped when a macroscopic total cytoreduction was achieved, or at the onset of neurological dysfunction. There was a higher rate of complete tumor resection (77% vs. 33%) and a lower rate of neurological deterioration (33% vs. 12%) in the study group compared to the control group. Overall, a complete resection in the study group was achieved in 40 patients (72%), a partial resection in 28%. Five patients developed a new deficit during surgery which resolved completely after a change of surgical strategy, 14 patients had a new deficit after surgery which improved within 3 months in 6 patients. There was no operative mortality.
CONCLUSION: The combination of neuronavigation with cortical stimulation and repetitive neurological and language examinations allows a more radical resection of tumors in eloquent brain areas, otherwise considered as inoperable.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058644     DOI: 10.1055/s-2007-985825

Source DB:  PubMed          Journal:  Minim Invasive Neurosurg        ISSN: 0946-7211


  6 in total

Review 1.  Awake craniotomy for supratentorial gliomas: why, when and how?

Authors:  George M Ibrahim; Mark Bernstein
Journal:  CNS Oncol       Date:  2012-09

2.  Impact of awake mapping on overall survival and extent of resection in patients with adult diffuse gliomas within or near eloquent areas: a retrospective propensity score-matched analysis of awake craniotomy vs. general anesthesia.

Authors:  Atsushi Fukui; Yoshihiro Muragaki; Taiichi Saito; Masayuki Nitta; Shunsuke Tsuzuki; Hidetsugu Asano; Takakazu Kawamata
Journal:  Acta Neurochir (Wien)       Date:  2021-10-04       Impact factor: 2.216

3.  Awake craniotomy for brain lesions within and near the primary motor area: A retrospective analysis of factors associated with worsened paresis in 102 consecutive patients.

Authors:  Nobusada Shinoura; Akira Midorikawa; Ryoji Yamada; Taijun Hana; Akira Saito; Kentaro Hiromitsu; Chisato Itoi; Syoko Saito; Kazuo Yagi
Journal:  Surg Neurol Int       Date:  2013-11-22

Review 4.  Current Limitations of Intraoperative Ultrasound in Brain Tumor Surgery.

Authors:  Andrej Šteňo; Ján Buvala; Veronika Babková; Adrián Kiss; David Toma; Alexander Lysak
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

Review 5.  Anaesthesia Management for Awake Craniotomy: Systematic Review and Meta-Analysis.

Authors:  Ana Stevanovic; Rolf Rossaint; Michael Veldeman; Federico Bilotta; Mark Coburn
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

6.  Resection of Gliomas with and without Neuropsychological Support during Awake Craniotomy-Effects on Surgery and Clinical Outcome.

Authors:  Anna Kelm; Nico Sollmann; Sebastian Ille; Bernhard Meyer; Florian Ringel; Sandro M Krieg
Journal:  Front Oncol       Date:  2017-08-18       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.